ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference
27 October 2009 - 9:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted anticancer products, today announced that its
presentation at the Oppenheimer 20th Annual Healthcare Conference
will be webcast live. The presentation is scheduled to begin at
1:00 p.m. ET on November 3, 2009, and will be given at the
Waldorf=Astoria hotel in New York. The presentation will provide an
update on the Company.
The webcast can be accessed through the Investor Information
section of the ImmunoGen website (www.immunogen.com). Following the
live webcast, a replay of the presentation will be available at the
same location until November 10, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cancer-cell killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s proprietary cancer-cell
killing agents specifically to cancer targets. In addition to the
Company’s product pipeline, compounds utilizing the TAP technology
are in clinical testing through ImmunoGen’s collaborations with
Genentech (a wholly-owned member of the Roche Group),
sanofi-aventis, Biogen Idec and Biotest. The most advanced
compound, trastuzumab-DM1 (T-DM1), is in Phase III testing
being conducted by Genentech and Roche. Other ImmunoGen
collaborative partners include Bayer HealthCare and Amgen. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024